The majority of patients with chronic‐phase (CP) chronic myeloid leukemia (CML) who are
treated with Bcr‐Abl tyrosine kinase inhibitors such as imatinib and dasatinib achieve …

The aim of the present study was to analyse the incidence of mutations in the BCR‑ABL1
kinase region in patients with newly diagnosed or treated chronic myeloid leukaemia (CML) …

Chronic myeloid leukemia (CML) has become a model for molecular targeted therapy [1]. It
is characterized by a cytogenetic marker, the Philadelphia (Ph) chromosome and its …

In chronic myeloid leukemia (CML), early treatment prediction is important to identify patients
with inferior overall outcomes. We examined the feasibility of using reductions in BCR-ABL1 …

Molecular monitoring of BCR–ABL transcript levels by real-time quantitative PCR is
increasingly used to assess treatment response in patients with chronic myeloid leukaemia …

FIgure 1. Possible future therapeutic strategy for CML. TKI: tyrosine kinase inhibitors; MMR:
major molecular response; MR: molecular response. phase CML where more than half of …

Chronic myeloid leukemia (CML) is a myeloproliferative disease, caused by BCR/ABL
protein with high tyrosine kinase activity. Since 2001, CML has been effectively treated with …

Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management. Most of
the CML patients achieve major responses, but a proportion (nearly 25–35%) of them …

The aim of oral tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML) is
to get ideal hematological, cytogenetic, molecular responses at the critical time points. The …

Abstract 2274 Patients with CML in chronic phase who have failed imatinib therapy are
commonly treated with dasatinib or nilotinib, but a significant proportion fail to respond or …